Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 14/20 | 0.60 |
| ▸ | MC5R | P33032 | 6/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MC1R | Q01726 | 4/20 | 0.44 |
| ▸ | MC3R | P41968 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1920425 | 1.00 | MC4R (0.60) | MC4RMC5RMEN1KMT2AMAPK1 | |
| SCHEMBL2762178 | 0.86 | KDM1A (0.50) | MC4RMC5RMEN1KMT2AMAPK1 | |
| SCHEMBL1920357 | 0.85 | MC4R (0.56) | MC4RMC5RMEN1KMT2A | |
| SCHEMBL1920198 | 0.84 | KMT2A (0.48) | MC4RMC5RMEN1KMT2A | |
| SCHEMBL3171390 | 0.83 | MC4R (0.46) | MC4RMC5RMC1RMC3R | |
| SCHEMBL1920391 | 0.82 | MC4R (0.64) | MC4RMC5RMC1RMC3R | |
| SCHEMBL3170759 | 0.82 | MC4R (0.64) | MC4RMC5RMC1RMC3R | |
| SCHEMBL91103 | 0.82 | MC4R (0.64) | MC4RMC5RMC1RMC3R | |
| SCHEMBL1920938 | 0.82 | MC4R (0.62) | MC4RMC5RMC1RMC3R | |
| SCHEMBL15252713 | 0.82 | MC4R (0.64) | MC4RMC5RMC1RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039622-B2 | Melanocortin receptor agonists | LG LIFE SCIENCES LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20110245500-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2011-10-06 | — | — | US | disclosed |
| US-20110237795-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG CHEM, LTD. (KR) | 2011-09-29 | — | — | US | disclosed |
| US-20110224219-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2011-09-15 | — | — | US | disclosed |
| EP-2350060-A2 | MELANOCORTIN RECEPTOR AGONISTS | LG Life Sciences Ltd (KR) | 2011-08-03 | — | — | EP | disclosed |
| EP-1716135-B1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LTD (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20100120783-A1 | MELANOCORTIN RECEPTOR AGONISTS | LG LIFE SCIENCE LTD. (KR) | 2010-05-13 | — | — | US | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
| EP-1716135-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | Pfizer Limited (GB) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077935-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LIMITED (GB) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237795-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | MC4R 4/4885MC5R 3/4885MEN1 899/4885 |
| US-20110245500-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | MC4R 4/4885MC5R 3/4885MEN1 899/4885 |
| US-20100120783-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | MC4R 4/4885MC5R 3/4885MEN1 899/4885 |
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | MC4R 1/4885MC5R 3/4885MEN1 179/4885 |
| US-20110224219-A1 | MELANOCORTIN RECEPTOR AGONISTS | MC1R, MC3R, MC5R | MC4R 4/4885MC5R 3/4885MEN1 899/4885 |
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | MC4R 1/4885MC5R 2/4885MEN1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.